Trion Pharma GmbH and its partner Fresenius Biotech GmbH remain on track to file for approval in Europe this year for their 'trifunctional antibody' removab (catumaxomab), which attained the primary endpoint and several secondary endpoints in a Phase II/III clinical trial in advanced cancer patients with malignant ascites. (BioWorld International) Read More
